Reporting from AACR 2023, Pierce Chow discusses the results of the IMbrave050 trial testing adjuvant atezolizumab plus bevacizumab versus active surveillance in high-risk hepatocellular carcinoma (HCC). This is landmark, the first trial of adjuvant treatment for HCC to show RFS improvement following resection or ablation. Longer follow-up is needed to evaluate if the difference observed in relapse occurrence will translate into a longer survival.
Abstract: CT003 - IMbrave050: Phase 3 study of adjuvant atezolizumab + bevacizumab versus active surveillance in patients with hepatocellular carcinoma (HCC) at high risk of disease recurrence following resection or ablation